{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:54:08Z","timestamp":1782824048073,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,2,2]],"date-time":"2015-02-02T00:00:00Z","timestamp":1422835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1038\/leu.2015.15","type":"journal-article","created":{"date-parts":[[2015,2,2]],"date-time":"2015-02-02T08:21:00Z","timestamp":1422865260000},"page":"1195-1201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma"],"prefix":"10.1038","volume":"29","author":[{"given":"R","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Apewokin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Grazziutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Yaccoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-7534","authenticated-orcid":false,"given":"S","family":"Atrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hoering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"J D","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Barlogie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,2]]},"reference":[{"key":"BFleu201515_CR1","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.2215\/CJN.12231212","volume":"8","author":"EC Heher","year":"2013","unstructured":"Heher EC, Rennke HG, Laubach JP, Richardson PG . Kidney disease and multiple myeloma. Clin J Am Soc Nephrol 2013; 8: 2007\u20132017.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFleu201515_CR2","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1001\/archinte.1990.00040031693017","volume":"150","author":"R Alexanian","year":"1990","unstructured":"Alexanian R, Barlogie B, Dixon D . Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693\u20131695.","journal-title":"Arch Intern Med"},{"key":"BFleu201515_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV . Crietria for diagnosis, staging and risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3\u20139.","journal-title":"Leukemia"},{"key":"BFleu201515_CR4","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1038\/leu.2008.131","volume":"22","author":"MA Dimopoulos","year":"2008","unstructured":"Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H . Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008; 22: 1485\u20131493.","journal-title":"Leukemia"},{"key":"BFleu201515_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2215\/CJN.02450706","volume":"2","author":"N Leung","year":"2007","unstructured":"Leung N, Dispenzieri A, Lacy MQ, Kumar SK, Hayman SR, Fervenza FC et al. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. Clin J Am Soc Nephrol 2007; 2: 440\u2013444.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFleu201515_CR6","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","volume":"28","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976\u20134984.","journal-title":"J Clin Oncol"},{"key":"BFleu201515_CR7","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/j.exphem.2006.07.010","volume":"34","author":"A Huston","year":"2006","unstructured":"Huston A, Brown J, Roodman GD . Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Exp Hematol 2006; 34: 1616.","journal-title":"Exp Hematol"},{"key":"BFleu201515_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","volume":"65","author":"LM Knudsen","year":"2000","unstructured":"Knudsen LM, Hjorth M, Hippe E . Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175\u2013181.","journal-title":"Eur J Haematol"},{"key":"BFleu201515_CR9","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842\u2013854.","journal-title":"Cancer"},{"key":"BFleu201515_CR10","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412\u20133420.","journal-title":"J Clin Oncol"},{"key":"BFleu201515_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.bcmd.2008.09.003","volume":"42","author":"F Perosa","year":"2009","unstructured":"Perosa F, Minoia C, Favoino E, Prete M, Dammacco F . Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count. Blood Cells Mol Dis 2009; 42: 71\u201376.","journal-title":"Blood Cells Mol Dis"},{"key":"BFleu201515_CR12","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","volume":"114","author":"A Badros","year":"2001","unstructured":"Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822\u2013829.","journal-title":"Br J Haematol"},{"key":"BFleu201515_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3324\/haematol.2013.087585","volume":"99","author":"C Scheid","year":"2014","unstructured":"Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65\/GMMG-HD4 trial. Haematologica 2014; 99: 148\u2013154.","journal-title":"Haematologica"},{"key":"BFleu201515_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1365-2141.2006.06191.x","volume":"134","author":"JM Bird","year":"2006","unstructured":"Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol 2006; 134: 385\u2013390, 20.","journal-title":"Br J Haematol"},{"key":"BFleu201515_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0609.2005.00446.x","volume":"75","author":"LM Knudsen","year":"2005","unstructured":"Knudsen LM, Nielsen B, Gimsing P, Geisler C . Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27\u201333.","journal-title":"Eur J Haematol"},{"key":"BFleu201515_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/10428190601126602","volume":"48","author":"V Eleutherakis-Papaiakovou","year":"2007","unstructured":"Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 2007; 48: 337\u2013341.","journal-title":"Leuk Lymphoma"},{"key":"BFleu201515_CR17","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","volume":"158","author":"J Blade","year":"1998","unstructured":"Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889\u20131893.","journal-title":"Arch Intern Med"},{"key":"BFleu201515_CR18","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"F Jesus","year":"2008","unstructured":"Jesus F, Miguel S, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O et al. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. N Engl J Med 2008; 359: 906\u2013917.","journal-title":"N Engl J Med"},{"key":"BFleu201515_CR19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/leu.2012.160","volume":"27","author":"SZ Usmani","year":"2013","unstructured":"Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B et al. Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia 2013; 27: 226\u2013232.","journal-title":"Leukemia"},{"key":"BFleu201515_CR20","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJMoa053583","volume":"354","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021\u20131030.","journal-title":"N Engl J Med"},{"key":"BFleu201515_CR21","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1182\/blood-2010-01-264333","volume":"116","author":"F Van Rhee","year":"2010","unstructured":"Van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 2010; 116: 1220\u20131227.","journal-title":"Blood"},{"key":"BFleu201515_CR22","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","volume":"115","author":"B Nair","year":"2010","unstructured":"Nair B, van Rhee F, Shaughnessy Jr JD, Anaissie E, Szymonifka J, Hoering A et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling\u2013defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010; 115: 4168\u20134173.","journal-title":"Blood"},{"key":"BFleu201515_CR23","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","volume":"124","author":"B Barlogie","year":"2014","unstructured":"Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan G, Crowley J . Curing myeloma at last-defining criteria and providing the evidence. Blood 2014; 124: 3043\u20133051.","journal-title":"Blood"},{"key":"BFleu201515_CR24","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JrJD Shaughnessy","year":"2007","unstructured":"Shaughnessy Jr JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109: 2276\u20132284.","journal-title":"Blood"},{"key":"BFleu201515_CR25","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/jmri.21970","volume":"30","author":"JP Kooman","year":"2009","unstructured":"Kooman JP . Estimation of renal function in patients with chronic kidney disease. J Magn Reson Imaging 2009; 30: 1341\u20131346.","journal-title":"J Magn Reson Imaging"},{"key":"BFleu201515_CR26","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N . Evaluation or survival data and two new rank order statistics srising in ots evaluation. Cancer Chemo Rep 1966; 50: 163\u2013170.","journal-title":"Cancer Chemo Rep"},{"key":"BFleu201515_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695\u2013706.","journal-title":"Stat Med"},{"key":"BFleu201515_CR28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR . Regression models and life-tables (with discussion). J Royal Statist Soc Series B 1972; 34: 187\u2013220.","journal-title":"J Royal Statist Soc Series B"},{"key":"BFleu201515_CR29","doi-asserted-by":"publisher","first-page":"9440","DOI":"10.1073\/pnas.1530509100","volume":"100","author":"JD Storey","year":"2003","unstructured":"Storey JD, Tibshirani R . Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440\u20139445.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu201515.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu201515","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu201515.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T23:19:42Z","timestamp":1717715982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,2]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["BFleu201515"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.15","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,2]]},"assertion":[{"value":"15 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Barlogie has received research funding from Celgene and Millennium, is a consultant to Celgene and Millennium, and is a co-inventor on patents and patent applications related to use of GEP in cancer medicine, that have been licensed to Myeloma Health, LLC.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}